Lilly's solanezumab shows promise against Alzheimer's

10/8/2012 | Bloomberg Businessweek

Eli Lilly and Co.'s solanezumab slowed memory loss and cognitive decline by approximately 30% in patients with early-stage Alzheimer's disease, showing the first evidence that a drug might prevent progression. The findings support the argument that beta-amyloid targeting benefits patients, said Rachelle Doody, Baylor College of Medicine's chairwoman of Alzheimer's research.

View Full Article in:

Bloomberg Businessweek

Published in Brief: